百洋医药：11月19日召开董事会会议

Group 1 - The core point of the article is that Baiyang Pharmaceutical announced the convening of its fourth board meeting to discuss a proposal regarding capital increase and related transactions with its wholly-owned subsidiary [1] - For the year 2024, Baiyang Pharmaceutical's revenue composition is as follows: sales of pharmaceuticals and medical devices account for 92.5%, brand services account for 7.18%, and other businesses account for 0.32% [1] - As of the time of reporting, Baiyang Pharmaceutical has a market capitalization of 11.9 billion yuan [1]